Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047X Temsirolimus endometrial adenocarcinoma predicted - sensitive detail...
FGFR2 N549K PRN1371 endometrial adenocarcinoma sensitive detail...
PIK3CA Q546X Copanlisib endometrial adenocarcinoma no benefit detail...
PIK3CA M1043I Copanlisib endometrial adenocarcinoma no benefit detail...
PIK3CA H1047X Copanlisib endometrial adenocarcinoma no benefit detail...
PIK3CA E545X Copanlisib endometrial adenocarcinoma no benefit detail...
PIK3CA E542K Copanlisib endometrial adenocarcinoma no benefit detail...
BRAF L597V Trametinib endometrial adenocarcinoma no benefit detail...
BRAF V600E Dabrafenib + Rabeprazole + Rifampin endometrial adenocarcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Rabeprazole + Rifampin + Trametinib endometrial adenocarcinoma predicted - sensitive detail...
FGFR2 K310R FGFR2 N549K RLY-4008 endometrial adenocarcinoma sensitive detail...
FGFR2 K310R FGFR2 N549K Futibatinib endometrial adenocarcinoma sensitive detail...
MLH1 negative Nivolumab endometrial adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00492778 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Active, not recruiting USA | CAN 0
NCT01482728 Phase I Dasatinib Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer Completed USA 0
NCT01877564 Phase II Metformin A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed USA 0
NCT02065687 Phase III Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Unknown status USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting USA 0
NCT02335203 Phase II Medroxyprogesterone The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy Unknown status USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU 1
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP 1
NCT03018249 Phase II Medroxyprogesterone Entinostat + Medroxyprogesterone Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Completed USA 0
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT03345784 Phase I Adavosertib + Cisplatin WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer Terminated USA | CAN 0
NCT03348631 Phase II Tazemetostat Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Active, not recruiting USA 0
NCT03586661 Phase I Copanlisib + Niraparib Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT03694262 Phase II Atezolizumab + Bevacizumab + Rucaparib The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) Completed USA 0
NCT03694834 Phase I Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer Terminated USA 0
NCT03832361 Phase II Mirvetuximab Soravtansine Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer Recruiting USA 0
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting USA | CAN 3
NCT04049227 Phase I Abemaciclib + Letrozole Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer Unknown status USA 0
NCT04291105 Phase II Cemiplimab + VSV-hIFNbeta-NIS Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Recruiting USA 1
NCT04393285 Phase II Abemaciclib + Letrozole Abemaciclib and Letrozole to Treat Endometrial Cancer Active, not recruiting USA 0
NCT04611139 Phase I Pembrolizumab + Seclidemstat Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers Withdrawn USA 0
NCT04719273 Phase II Anastrozole + Onapristone Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer Active, not recruiting USA 0
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Active, not recruiting USA 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Recruiting NLD | GBR | FRA | CAN 0
NCT05276973 Phase I Carboplatin + Ipatasertib + Paclitaxel Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Recruiting USA 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 16
NCT05332483 Phase I Megestrol acetate Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC) Terminated CAN 0
NCT05538897 Phase Ib/II Megestrol acetate Ipatasertib + Megestrol acetate Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Recruiting USA 0
NCT05548296 Phase Ib/II Prexasertib Gemcitabine + Prexasertib A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Recruiting USA 0
NCT05603910 Phase I Lenvatinib + Pembrolizumab Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Recruiting USA 0
NCT05611931 Phase III Selinexor Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) Recruiting USA | ITA | ESP | DEU | CAN | BEL | AUS 7
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05705505 Phase Ib/II Letrozole + Narazaciclib Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer Recruiting USA 0
NCT05712941 Phase III G1T38 + Letrozole Letrozole Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer Withdrawn 0
NCT05761951 Phase II DKN-01 + Pembrolizumab Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer Recruiting USA 0
NCT05826015 Phase I AVB-S6-500 AVB-S6-500 + Paclitaxel AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer Not yet recruiting USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05950464 Phase I M1774 + ZEN-3694 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer Recruiting USA 0
NCT05997017 Phase II Nab-rapamycin Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer Recruiting USA 0
NCT06003231 Phase II Disitamab vedotin A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting USA | CAN | AUS 0
NCT06178614 Phase I JNJ-87890387 A Study of JNJ-87890387 for Advanced Solid Tumors Recruiting USA | FRA | ESP 0
NCT06278857 Phase II Dostarlimab-gxly SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (SATELLITE) Not yet recruiting AUS 0
NCT06366347 Phase II Pembrolizumab Abemaciclib + Letrozole ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Not yet recruiting USA 0